ASCELIA PHARMA IS AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY
Ascelia Pharma is listed on Nasdaq Stockholm
Ascelia Pharma is listed on Nasdaq Stockholm main market (small cap) under the ticker ACE
Product pipeline
Lead candidate Mangoral (phase III ready) is an MRI imaging drug being developed for detection and localization of liver metastases.
Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.
Events
- November 8 @ 08:00
Ascelia Pharma interim report Q1 (Jul-Sep 2019) for fiscal year 2019/2020
- November 14 @ 10:00 - 12:00
Ascelia Pharma Annual General Meeting
- November 22
Redeye Life Science Day
Latest news
- 2019-09-11Ascelia Pharma to present at Redeye seminar in Malmö on 12 September 2019
- 2019-09-06Ascelia Pharma to present at Share Day (Aktiedagen) in Stockholm on 10 September 2019
- 2019-08-22Full-year financial report 2018/2019: Phase III study of Mangoral to start in H2-2019
- 2019-08-20Invitation to presentation of Ascelia Pharma’s Q4 report 2018/2019
- 2019-06-10Ascelia Pharma strengthens its Mangoral franchise by filing of a patent application for next generation Mangoral product